多发性创伤患者早期全身反应中可检测到病毒微RNA,并与预后相关
本研究为前瞻性多中心创伤数据库的子集分析,纳入180例ISS≥16的成人多发性创伤患者,于入创伤抢救室时(T0)采血。多因素LASSO分析显示,miR-BHRF-1、miR-K12-12、MCP-1和HGF是复杂恢复的独立预测因子,模型AUC为0.81。提示病毒微RNA在创伤早期即被转录,可能与多发性创伤后复杂恢复相关。
要点
- 纳入成人多发性创伤患者180例,ISS≥16,于入创伤抢救室时(T0)采集血浆样本。
- 复杂恢复定义为ICU入住>14天、机械通气>7天或28天内死亡,本队列发生率为33%。
- 多因素LASSO分析显示miR-BHRF-1、miR-K12-12、MCP-1和HGF为复杂恢复的独立预测因子,模型AUC为0.81。
- 单因素分析显示病毒微RNA与年龄、种族及伤后并发症相关;IL-10是全部病毒微RNA的最强预测因子。
适用人群与场景
- 成人多发性创伤患者,损伤严重度评分(ISS)≥16,且有T0血浆样本可用。
- 样本来自两个民用一级创伤中心和一个军事治疗机构,为前瞻性多中心创伤数据库的子集分析。
- 排除标准原文未明确列出;复杂恢复定义为ICU入住>14天、机械通气>7天或28天内死亡。
诊断标准与关键阈值
- 复杂恢复定义:ICU入住大于14天,或机械通气大于7天,或28天内死亡。
- 损伤严重度评分(ISS)≥16为纳入条件之一。
- T0定义为入创伤抢救室时采血的时间点。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:前瞻性多中心创伤数据库的子集分析;样本量n=180;中心数:两个民用一级创伤中心和一個军事治疗机构。
- 人群:成人多发性创伤患者,ISS≥16,有T0血浆样本;复杂恢复发生率为33%。
- 检测方法:T0血浆行逆转录定量聚合酶链反应检测KSHV微RNA(miR-K12_10b和miR-K12-12)和EBV微RNA(miR-BHRF-1),并行Luminex多重阵列分析炎症介质。
- 多因素LASSO分析:IL-10是全部病毒微RNA的最强预测因子;miR-BHRF-1、miR-K12-12、MCP-1和HGF为复杂恢复的独立预测因子,模型AUC为0.81。
- 单因素分析:病毒微RNA与年龄、种族及伤后并发症相关。
证据类型、等级与局限
- 证据类型:前瞻性多中心创伤数据库的子集分析(观察性研究)。
- 证据等级或推荐强度:原文未提及。
- 局限:原文未明确列出局限;设计上为子集分析、观察性研究,样本量n=180。
对床旁实践的改变
- 本研究提示多发性创伤患者伤后数小时内即可检测到病毒微RNA,且与复杂恢复独立相关,但为观察性关联,尚不能作为床旁决策阈值。
- 病毒微RNA检测目前为研究性手段,原文未给出临床可用的检测流程、阈值或干预措施,不改变现有创伤复苏与ICU管理做法。
- 适用人群为ISS≥16的成人多发性创伤患者;不适用于原文未纳入的人群(如儿童、非多发性创伤患者),原文未提及这些人群的数据。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate early activation of latent viruses in polytrauma patients and consider prognostic value of viral micro-RNAs in these patients.
DESIGN: This was a subset analysis from a prospectively collected multicenter trauma database. Blood samples were obtained upon admission to the trauma bay (T0), and trauma metrics and recovery data were collected.
SETTING: Two civilian Level 1 Trauma Centers and one Military Treatment Facility.
PATIENTS: Adult polytrauma patients with Injury Severity Scores greater than or equal to 16 and available T0 plasma samples were included in this study. Patients with ICU admission greater than 14 days, mechanical ventilation greater than 7 days, or mortality within 28 days were considered to have a complicated recovery.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Polytrauma patients (n = 180) were identified, and complicated recovery was noted in 33%. Plasma samples from T0 underwent reverse transcriptase-quantitative polymerase chain reaction analysis for Kaposi's sarcoma-associated herpesvirus micro-RNAs (miR-K12_10b and miRK-12-12) and Epstein-Barr virus-associated micro-RNA (miR-BHRF-1), as well as Luminex multiplex array analysis for established mediators of inflammation. Ninety-eight percent of polytrauma patients were found to have detectable Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus micro-RNAs at T0, whereas healthy controls demonstrated 0% and 100% detection rate for Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus, respectively. Univariate analysis revealed associations between viral micro-RNAs and polytrauma patients' age, race, and postinjury complications. Multivariate least absolute shrinkage and selection operator analysis of clinical variables and systemic biomarkers at T0 revealed that interleukin-10 was the strongest predictor of all viral micro-RNAs. Multivariate least absolute shrinkage and selection operator analysis of systemic biomarkers as predictors of complicated recovery at T0 demonstrated that miR-BHRF-1, miR-K12-12, monocyte chemoattractant protein-1, and hepatocyte growth factor were independent predictors of complicated recovery with a model complicated recovery prediction area under the curve of 0.81.
CONCLUSIONS: Viral micro-RNAs were detected within hours of injury and correlated with poor outcomes in polytrauma patients. Our findings suggest that transcription of viral micro-RNAs occurs early in the response to trauma and may be associated with the biological processes involved in polytrauma-induced complicated recovery.
参考来源
- Vicente D, Schobel SA, Anfossi S, et al. Viral Micro-RNAs Are Detected in the Early Systemic Response to Injury and Are Associated With Outcomes in Polytrauma Patients. Crit Care Med. 2022. PMID: 34259445. doi:10.1097/CCM.0000000000005181
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。